RU2012134065A - Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления - Google Patents
Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления Download PDFInfo
- Publication number
- RU2012134065A RU2012134065A RU2012134065/15A RU2012134065A RU2012134065A RU 2012134065 A RU2012134065 A RU 2012134065A RU 2012134065/15 A RU2012134065/15 A RU 2012134065/15A RU 2012134065 A RU2012134065 A RU 2012134065A RU 2012134065 A RU2012134065 A RU 2012134065A
- Authority
- RU
- Russia
- Prior art keywords
- intraocular pressure
- weight
- benzimidazole
- bromo
- ylamino
- Prior art date
Links
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 26
- 230000004410 intraocular pressure Effects 0.000 claims abstract 19
- 239000000203 mixture Substances 0.000 claims abstract 15
- JHOJNZYPXCAPKL-UHFFFAOYSA-N 4-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-benzimidazol-5-amine Chemical compound C1=CC=2NC=NC=2C(Br)=C1N=C1NCCN1 JHOJNZYPXCAPKL-UHFFFAOYSA-N 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000003755 preservative agent Substances 0.000 claims abstract 6
- 230000002335 preservative effect Effects 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000006184 cosolvent Substances 0.000 claims abstract 2
- 230000001839 systemic circulation Effects 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
- 239000005022 packaging material Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 210000001742 aqueous humor Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29691210P | 2010-01-21 | 2010-01-21 | |
| US61/296,912 | 2010-01-21 | ||
| PCT/US2011/022001 WO2011091225A2 (en) | 2010-01-21 | 2011-01-21 | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012134065A true RU2012134065A (ru) | 2014-02-27 |
Family
ID=44169074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012134065/15A RU2012134065A (ru) | 2010-01-21 | 2011-01-21 | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9889088B2 (enExample) |
| EP (1) | EP2525793B1 (enExample) |
| JP (3) | JP2013518051A (enExample) |
| KR (1) | KR20120125305A (enExample) |
| CN (1) | CN102770135A (enExample) |
| AU (1) | AU2011207301A1 (enExample) |
| BR (1) | BR112012018154A2 (enExample) |
| CA (1) | CA2787573A1 (enExample) |
| CL (1) | CL2012002038A1 (enExample) |
| CO (1) | CO6592108A2 (enExample) |
| IL (1) | IL221030A0 (enExample) |
| MX (1) | MX2012008516A (enExample) |
| RU (1) | RU2012134065A (enExample) |
| SG (1) | SG182637A1 (enExample) |
| TW (1) | TW201141477A (enExample) |
| WO (1) | WO2011091225A2 (enExample) |
| ZA (1) | ZA201205470B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842866A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| KR20150126619A (ko) * | 2013-03-14 | 2015-11-12 | 알러간, 인코포레이티드 | 유리체강내 및 전방내 경로를 통해 안압 및 안구 질환을 치료하기 위한 알파-2 아드레날린 작용제 |
| TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
| EP3647420B1 (en) | 2017-06-27 | 2023-08-23 | The University Of Tokyo | Probe and method for detecting transcript resulting from fusion gene and/or exon skipping |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| AU2021369566A1 (en) * | 2020-11-02 | 2023-06-22 | Visus Therapeutics, Inc. | Degradant compound in a medicament |
| EP4429652A4 (en) * | 2021-11-10 | 2025-09-10 | Visus Therapeutics Inc | CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| AU704972B2 (en) * | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP2009500409A (ja) * | 2005-06-29 | 2009-01-08 | アラーガン、インコーポレイテッド | 痛みを処置するためのα２アドレナリン作動剤 |
| EP1981852A1 (en) * | 2006-02-06 | 2008-10-22 | NicOx S.A. | Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
-
2011
- 2011-01-21 AU AU2011207301A patent/AU2011207301A1/en not_active Abandoned
- 2011-01-21 BR BR112012018154A patent/BR112012018154A2/pt not_active IP Right Cessation
- 2011-01-21 KR KR1020127021719A patent/KR20120125305A/ko not_active Withdrawn
- 2011-01-21 US US13/010,958 patent/US9889088B2/en active Active
- 2011-01-21 EP EP11702342.4A patent/EP2525793B1/en not_active Not-in-force
- 2011-01-21 WO PCT/US2011/022001 patent/WO2011091225A2/en not_active Ceased
- 2011-01-21 RU RU2012134065/15A patent/RU2012134065A/ru unknown
- 2011-01-21 CN CN2011800111530A patent/CN102770135A/zh active Pending
- 2011-01-21 MX MX2012008516A patent/MX2012008516A/es unknown
- 2011-01-21 TW TW100102411A patent/TW201141477A/zh unknown
- 2011-01-21 CA CA2787573A patent/CA2787573A1/en not_active Abandoned
- 2011-01-21 JP JP2012550140A patent/JP2013518051A/ja active Pending
- 2011-01-21 SG SG2012053815A patent/SG182637A1/en unknown
-
2012
- 2012-07-19 IL IL221030A patent/IL221030A0/en unknown
- 2012-07-20 ZA ZA2012/05470A patent/ZA201205470B/en unknown
- 2012-07-20 CL CL2012002038A patent/CL2012002038A1/es unknown
- 2012-08-17 CO CO12140238A patent/CO6592108A2/es not_active Application Discontinuation
-
2015
- 2015-10-28 JP JP2015211447A patent/JP2016026206A/ja active Pending
-
2017
- 2017-04-26 JP JP2017086952A patent/JP6466504B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6466504B2 (ja) | 2019-02-06 |
| JP2016026206A (ja) | 2016-02-12 |
| IL221030A0 (en) | 2012-09-24 |
| BR112012018154A2 (pt) | 2016-04-05 |
| JP2013518051A (ja) | 2013-05-20 |
| SG182637A1 (en) | 2012-08-30 |
| EP2525793B1 (en) | 2018-09-05 |
| JP2017125074A (ja) | 2017-07-20 |
| MX2012008516A (es) | 2012-10-15 |
| US9889088B2 (en) | 2018-02-13 |
| CN102770135A (zh) | 2012-11-07 |
| WO2011091225A3 (en) | 2012-05-18 |
| CA2787573A1 (en) | 2011-07-28 |
| CO6592108A2 (es) | 2013-01-02 |
| CL2012002038A1 (es) | 2012-11-16 |
| ZA201205470B (en) | 2013-05-29 |
| TW201141477A (en) | 2011-12-01 |
| WO2011091225A2 (en) | 2011-07-28 |
| KR20120125305A (ko) | 2012-11-14 |
| US20110178145A1 (en) | 2011-07-21 |
| EP2525793A2 (en) | 2012-11-28 |
| AU2011207301A1 (en) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| JP2013518051A5 (enExample) | ||
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| MX361590B (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| JP2016539921A5 (enExample) | ||
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| JP5872131B2 (ja) | 抗真菌医薬組成物 | |
| JP7787129B2 (ja) | 眼科組成物 | |
| MX2013006816A (es) | Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol. | |
| RU2013111633A (ru) | Стабильная жидкая фармацевтическая композиция комплекса 3-(2,2,2-триметилгидразиний) пропионат-2-этил-6-метил-3-гидроксипиридина дисукцината, обладающая антигипоксическим, антиоксидантным и адаптогенным действием | |
| JP2016537364A5 (enExample) | ||
| RU2013141836A (ru) | Способы и композиции для лечения болезни рейно | |
| JP2016538288A5 (enExample) | ||
| RU2013124526A (ru) | Фармацевтические композиции, содержащие (3-(1-(1н-имидазол-4-ил)этил)-2-метилфенил) метанол | |
| MX2016008546A (es) | Reduccion de queloides utilizando alantoina topica. | |
| JP2014530847A5 (enExample) | ||
| JP6333023B2 (ja) | 水性医薬組成物 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| ZA202400915B (en) | Pharmaceutical composition and use thereof | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно |